Search
  • Site Search
  • News
  • Product
  • Zhejiang Medical Technology Development Co., Ltd.

    2018 year
    10
    20 day
    20th anniversary celebration of marketing of Mucosolvan successfully held

    On October 20, the 20th anniversary celebration of marketing of Mucosolvan (Mucosolvan Hydrochloride Injection), which was sponsored jointly by Winhealth Group and Boehringer Ingelheim, was held in Hangzhou. Thousands of experts, scholars and clinicians from all over the country attended this grand gathering in the form of on-site participation or network broadcast. 


    At the celebration, experts in pneumology, ICU, thoracic surgery, pharmacy and other fields shared the application status and latest treatment progress of Mucosolvan in various treatment fields from their respective disciplines, and had heated discussions and exchanges with the participants. 

     

     20th anniversary celebration of marketing of Mucosolvan successfully held  20th anniversary celebration of marketing of Mucosolvan successfully held

     

    At the opening of the celebration, Mr. Wang, Chief Executive Officer of Winhealth Group, delivered a speech. He said that he was very honored to cooperate with Boehringer Ingelheim China, and to provide Chinese patients and doctors with Mucosolvan Injection, a classic product widely recognized in the respiratory field. He expressed thanks to the paticipants for their coming and looked forward to witnessing another 20th anniversary celebration with them! 


    In his speech, Mr. Dirk van Niekerk said, 'Mucosolvan Injection has been widely used in clinical practice in the past 20 years, benefiting numerous Chinese patients. Boehringer Ingelheim is very proud of having developed and manufactured this classic drug. 

      

    20th anniversary celebration of marketing of Mucosolvan successfully held  20th anniversary celebration of marketing of Mucosolvan successfully held

     

    On January 1, 2018, Winhealth Group and BI signed a 10-year strategic cooperation agreement. As a classic drug in the respiratory field, Mucosolvan is developed and produced by Boehringer Ingelheim. As a mucodynamic drug, it is widely used to treat airway mucous hypersecretion diseases, such as asthma attack, and acute exacerbation of chronic obstructive pulmonary disease. 


    Meanwhile, due to its unique and comprehensive lung protection mechanism, it is also recommended by authoritative guidelines for perioperative thoracic surgery and ICU. Since it was marketed in China in 1999, its efficacy and safety have been verified by a large number of evidence-based medical research and clinical practice, have been widely recognized by clinicians and have benefited numerous patients. 

     

    20th anniversary celebration of marketing of Mucosolvan successfully held  20th anniversary celebration of marketing of Mucosolvan successfully held


    20th anniversary celebration of marketing of Mucosolvan successfully held


    In addition, Winhealth Group also set up 19 sub-venues across the country to hold the 20th anniversary celebration of Mucosolvan's marketing simultaneously, allowing more medical experts and scholars to witness this grand occasion. 


    Winhealth Pharmaceutical Group is a third-party pharmaceutical service company with an integrated professional service system in the Chinese market, whose services cover drug registration application, product import, market access, promotion and sales. We are committed to introducing the world's leading health products and medical technologies into the Chinese market, so as to provide medical workers with more advanced treatment methods and medical information dissemination channels, and to provide patients with more treatment and rehabilitation resources. 

    3rd Floor, Winhealth Industrial Park, No. 272 Huancheng East Road, Xiacheng District, Hangzhou, Zhejiang, China
    BD@winhealth.Hk (overseas)
    0571-8718 6358    4008393773 ( Product Hotline )
    Copyright ©2019 - 2024 Zhejiang Medical Technology Development Co., Ltd.